» Articles » PMID: 31014012

Protects D-Galactose/AlCl Mediated Alzheimer's Disease-Like Rats Via PP2A/GSK-3β Signaling Pathway in Their Hippocampus

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2019 Apr 25
PMID 31014012
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder more prevalent among the elderly population. AD is characterised clinically by a progressive decline in cognitive functions and pathologically by the presence of neurofibrillary tangles (NFTs), deposition of beta-amyloid (Aβ) plaque and synaptic dysfunction in the brain. (CA) is a valuable herb being used widely in African, Ayurvedic, and Chinese traditional medicine to reverse cognitive impairment and to enhance cognitive functions. This study aimed to evaluate the effectiveness of CA in preventing d-galactose/aluminium chloride (d-gal/AlCl) induced AD-like pathologies and the underlying mechanisms of action were further investigated for the first time. Results showed that co-administration of CA to d-gal/AlCl induced AD-like rat models significantly increased the levels of protein phosphatase 2 (PP2A) and decreased the levels of glycogen synthase kinase-3 beta (GSK-3β). It was further observed that, CA increased the expression of mRNA of Bcl-2, while there was minimal effect on the expression of caspase 3 mRNA. The results also showed that, CA prevented morphological aberrations in the connus ammonis 3 (CA 3) sub-region of the rat's hippocampus. The results clearly demonstrated for the first time that CA could alleviate d-gal/AlCl induced AD-like pathologies in rats via inhibition of hyperphosphorylated tau (P-tau) bio-synthetic proteins, anti-apoptosis and maintenance of cytoarchitecture.

Citing Articles

Effectiveness and mechanisms of combined use of antioxidant nutrients in protecting against oxidative stress-induced neuronal loss and related neurological deficits.

Wang L, Wei Y, Sun Z, Tai W, Li H, Yin Y CNS Neurosci Ther. 2024; 30(7):e14886.

PMID: 39072940 PMC: 11284237. DOI: 10.1111/cns.14886.


Neuroprotective Action of Selected Natural Drugs Against Neurological Diseases and Mental Disorders: Potential Use Against Radiation Damage.

Akhlada , Siddiqui N, Anurag , Saifi A, Kesharwani A, Parihar V Neurochem Res. 2024; 49(9):2336-2351.

PMID: 38864943 DOI: 10.1007/s11064-024-04184-y.


Progress in the correlation of postoperative cognitive dysfunction and Alzheimer's disease and the potential therapeutic drug exploration.

Chen D, Fang X, Zhu Z Ibrain. 2024; 9(4):446-462.

PMID: 38680509 PMC: 11045201. DOI: 10.1002/ibra.12040.


3-Acetyl coumarin alleviate neuroinflammatory responses and oxidative stress in aluminum chloride-induced Alzheimer's disease rat model.

Zeb Z, Sharif A, Akhtar B, Shahnaz Inflammopharmacology. 2024; 32(2):1371-1386.

PMID: 38448794 DOI: 10.1007/s10787-024-01434-x.


Herbal Therapeutics for Alzheimer's Disease: Ancient Indian Medicine System from the Modern Viewpoint.

Kushwah S, Maurya N, Kushwaha S, Scotti L, Chawade A, Mani A Curr Neuropharmacol. 2023; 21(4):764-776.

PMID: 36797613 PMC: 10227917. DOI: 10.2174/1570159X21666230216094353.


References
1.
Sharma D, Wani W, Sunkaria A, Kandimalla R, Sharma R, Verma D . Quercetin attenuates neuronal death against aluminum-induced neurodegeneration in the rat hippocampus. Neuroscience. 2016; 324:163-76. DOI: 10.1016/j.neuroscience.2016.02.055. View

2.
Donahue J, Flaherty S, Johanson C, Duncan 3rd J, Silverberg G, Miller M . RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol. 2006; 112(4):405-15. DOI: 10.1007/s00401-006-0115-3. View

3.
Soumyanath A, Zhong Y, Henson E, Wadsworth T, Bishop J, Gold B . Centella asiatica Extract Improves Behavioral Deficits in a Mouse Model of Alzheimer's Disease: Investigation of a Possible Mechanism of Action. Int J Alzheimers Dis. 2012; 2012:381974. PMC: 3296229. DOI: 10.1155/2012/381974. View

4.
Xing Z, He Z, Wang S, Yan Y, Zhu H, Gao Y . Ameliorative effects and possible molecular mechanisms of action of fibrauretine from Pierre on d-galactose/AlCl-mediated Alzheimer's disease. RSC Adv. 2022; 8(55):31646-31657. PMC: 9085853. DOI: 10.1039/c8ra05356a. View

5.
Eldar-Finkelman H . Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med. 2002; 8(3):126-32. DOI: 10.1016/s1471-4914(01)02266-3. View